<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Adv</journal-id><journal-id journal-id-type="iso-abbrev">Sci Adv</journal-id><journal-id journal-id-type="publisher-id">sciadv</journal-id><journal-id journal-id-type="hwp">advances</journal-id><journal-title-group><journal-title>Science Advances</journal-title></journal-title-group><issn pub-type="epub">2375-2548</issn><publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40397734</article-id><article-id pub-id-type="pmc">PMC12094233</article-id><article-id pub-id-type="publisher-id">adu8678</article-id><article-id pub-id-type="doi">10.1126/sciadv.adu8678</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Social and Interdisciplinary Sciences and Public Health</subject></subj-group><subj-group subj-group-type="legacy-article-type"><subject>SciAdv r-articles</subject></subj-group><subj-group subj-group-type="field"><subject>Epidemiology</subject><subject>Public Health</subject></subj-group><subj-group subj-group-type="overline"><subject>Public Health</subject></subj-group></article-categories><title-group><article-title>Socioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023</article-title><alt-title alt-title-type="short">SARS-CoV-2 risk heterogeneity drivers in England</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3735-1130</contrib-id><name><surname>Morgenstern</surname><given-names>Christian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8182-4279</contrib-id><name><surname>Rawson</surname><given-names>Thomas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4597-1746</contrib-id><name><surname>Hinsley</surname><given-names>Wes</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5277-5196</contrib-id><name><surname>Perez Guzman</surname><given-names>Pablo N.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0891-4611</contrib-id><name><surname>Bhatt</surname><given-names>Samir</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1154-8093</contrib-id><name><surname>Ferguson</surname><given-names>Neil M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><aff id="aff1"><label><sup>1</sup></label>MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK.</aff><aff id="aff2"><label><sup>2</sup></label>University of Copenhagen, Copenhagen, Denmark.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="c.morgenstern@imperial.ac.uk">c.morgenstern@imperial.ac.uk</email></corresp><fn id="afn1" fn-type="equal"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>21</day><month>5</month><year>2025</year></pub-date><volume>11</volume><issue>21</issue><elocation-id>eadu8678</elocation-id><history>
<date date-type="received"><day>26</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-05-21">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution license</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="sciadv.adu8678.pdf"/><abstract><p>The impact of COVID-19 varied significantly by deprivation, ethnicity, and policy measures. We analyzed individual-level data on 12,310,485 first SARS-CoV-2 Pillar 2&#x02013;PCR-confirmed infections, 439,083 hospitalizations, 107,823 deaths, and vaccination records in England from May 2020 to February 2022. Poisson regression models adjusted for demographic and temporal factors showed higher incidence rate ratios (IRRs) for severe outcomes in the most deprived areas compared to the least. We note higher IRRs for severe outcomes for all non-white relative to white ethnicities. The magnitude of IRRs for both deprivation and ethnicities declined from the wild-type to the omicron periods for severe outcomes. For infections, we observed IRRs above one for non-white ethnicities during the wild-type and alpha periods. Vaccination significantly reduced risks across all groups. For severe outcomes, preexisting health inequalities led to large and persistent disparities. For infections, measures must be structured with ethnicity and deprivation in mind early in a pandemic.</p></abstract><abstract abstract-type="teaser"><p>Deprivation and ethnicity influenced COVID-19 outcomes, revealing health inequalities and vaccine effectiveness in the pandemic.</p></abstract><funding-group><award-group id="award1862099"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100027426</institution-id><institution>Schmidt Futures</institution></institution-wrap>
</funding-source><award-id>G-22-63345</award-id></award-group><award-group id="award1862095"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap>
</funding-source><award-id>MR/X020258/1</award-id></award-group><award-group id="award1862098"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001732</institution-id><institution>Danish National Research Foundation</institution></institution-wrap>
</funding-source><award-id>DNRF160</award-id></award-group><award-group id="award1862097"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004191</institution-id><institution>Novo Nordisk</institution></institution-wrap>
</funding-source><award-id>NNF20OC0059309</award-id></award-group><award-group id="award1862096"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NIHR Health Research Protection Unit in Modelling and Health Economics</institution></institution-wrap>
</funding-source><award-id>NIHR200908</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="introduction" disp-level="1"><title>INTRODUCTION</title><p>By December 2023, the COVID-19 pandemic had caused more than 20.5 million confirmed cases and more than 175,000 deaths in England (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>, <xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>). The pandemic did not affect individuals equally; individual-based studies have explored the links between deprivation, ethnicity, and other factors on health outcomes to varying levels (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>&#x02013;<xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>).</p><p>Past studies have explored heterogeneity in risk in England (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>, <xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>) and Scotland (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>) using the index of multiple deprivation (IMD) (<xref rid="R12" ref-type="bibr"><italic toggle="yes">12</italic></xref>) at the lower-tier local authority (LTLA) level. LTLAs are areas where local government provides services, and the UK Office of National Statistics (ONS) provides an extensive set of data, including population age distribution, ethnicity, and measures of deprivation. These measures vary substantially across LTLAs, as did the number of polymerase chain reaction (PCR)&#x02013;confirmed infections, hospitalizations, and deaths reported across England over the course of the pandemic (<xref rid="F1" ref-type="fig">Fig. 1</xref>). In this study, we aim to characterize this heterogeneity in COVID-19 outcomes and how it evolved during the pandemic (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>, <xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>, <xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). Similar studies on the impact of socioeconomic heterogeneities on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been conducted in France (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>) and Germany (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>) and on outcomes in the USA (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>).</p><fig position="float" id="F1" fig-type="image" specific-use="distribute"><label>Fig. 1.</label><caption><title>Maps of the population of England at the LTLA level between 10 May 2020 and 27 February 2022.</title><p>(<bold>A</bold>) IMD quintile by LTLA, (<bold>B</bold>) percentage of non-white population within the LTLA by LTLA, (<bold>C</bold>) percentage of individuals vaccinated with at least two doses for all ages, (<bold>D</bold>) percentage of positive Pillar 2 PCR-confirmed first recorded cases by LTLA, (<bold>E</bold>) percentage of hospitalization by LTLA, and (<bold>F</bold>) percentage deaths by LTLA.</p></caption><graphic xlink:href="sciadv.adu8678-f1" position="float"/></fig><p>SARS-CoV-2 testing in England (<xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>) had four &#x0201c;pillars&#x0201d;: PCR testing for health and care workers and individuals with clinical needs (Pillar 1), freely available PCR (and later antigen) testing for the general population (Pillar 2), serology (Pillar 3), and targeted surveillance (Pillar 4). Pillar 2 testing increased significantly from 10 May 2020, and most testing was halted on 27 February 2022 with the introduction of the &#x0201c;Living with COVID&#x0201d; strategy (<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>) (see Materials and Methods and section C.4).</p><p>We additionally investigate vaccine effectiveness (VE) in the postvaccination period and the impact of vaccination on risk heterogeneity. The SARS-CoV-2 immunization program in England was one of the most rapid globally, with 89.9% of the adult population aged 20 or over receiving at least one dose and 86.6% receiving at least two doses by 27 February 2022 (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Test-negative case-control studies (TNCCs) were the standard epidemiological tool for evaluating SARS-CoV-2 VE during the pandemic (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>&#x02013;<xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>), although TNCCs can potentially suffer from biases (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). The main alternative to TNCCs used for VE estimation during the COVID-19 pandemic is large population observational cohort studies that use individual-level health care and surveillance data linked to vaccination status (<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>&#x02013;<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Last, we investigate how risk heterogeneity was modified by the public health measures (&#x0201c;restrictions&#x0201d;) in force during the pandemic (see Materials and Methods and section C.3) (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>, <xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>).</p></sec><sec sec-type="results" disp-level="1"><title>RESULTS</title><p>We present the breakdown of the population of England [56,427,863 people in England (Census 2021), 56,417,353 are in our synthetic population, and 56,344,410 are included in the analysis] in <xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T2" ref-type="table">2</xref>, including the number of first recorded PCR-confirmed SARS-CoV-2 infections (12,310,485) and associated hospitalizations (439,083) or deaths (107,823) linked to that first recorded infection from the week beginning 10 May 2020 (isoweek 18) to 27 February 2022 (isoweek 8) confirmed by a Pillar 2 PCR-positive test. These 95 weeks cover the full period for which population-wide testing was available.</p><table-wrap position="float" id="T1"><label>Table 1.</label><caption><title>Population for England with numbers of first recorded Pillar 2 PCR-confirmed SARS-CoV-2, hospitalizations, and deaths in England between 10 May 2020 and 27 February 2022.</title><p>Population breakdown by sex, age, region, deprivation, and ethnicity.</p></caption><table frame="hsides" rules="groups"><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Variable</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Category</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Person-days at risk</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Cases (Pillar 2 PCR)</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Hospitalizations</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Deaths</th></tr></thead><tbody><tr><td rowspan="2" valign="middle" align="left" colspan="1">Sex</td><td valign="bottom" align="center" rowspan="1" colspan="1">Female</td><td valign="bottom" align="center" rowspan="1" colspan="1">28,685,081</td><td valign="bottom" align="center" rowspan="1" colspan="1">17,345,400,702</td><td valign="bottom" align="center" rowspan="1" colspan="1">6,517,293</td><td valign="bottom" align="center" rowspan="1" colspan="1">222,651</td><td valign="bottom" align="center" rowspan="1" colspan="1">49,389</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Male</td><td valign="bottom" align="center" rowspan="1" colspan="1">27,659,329</td><td valign="bottom" align="center" rowspan="1" colspan="1">16,807,116,305</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,793,192</td><td valign="bottom" align="center" rowspan="1" colspan="1">216,432</td><td valign="bottom" align="center" rowspan="1" colspan="1">58,434</td></tr><tr><td rowspan="6" valign="middle" align="left" colspan="1">Age</td><td valign="bottom" align="center" rowspan="1" colspan="1">Under 40</td><td valign="bottom" align="center" rowspan="1" colspan="1">28,863,746</td><td valign="bottom" align="center" rowspan="1" colspan="1">17,378,043,704</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,986,079</td><td valign="bottom" align="center" rowspan="1" colspan="1">97,480</td><td valign="bottom" align="center" rowspan="1" colspan="1">1246</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">40&#x02013;49</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,126,246</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,298,749,448</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,832,839</td><td valign="bottom" align="center" rowspan="1" colspan="1">40,577</td><td valign="bottom" align="center" rowspan="1" colspan="1">2211</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">50&#x02013;59</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,574,556 </td><td valign="bottom" align="center" rowspan="1" colspan="1">4,665,987,550</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,400,202</td><td valign="bottom" align="center" rowspan="1" colspan="1">56,807</td><td valign="bottom" align="center" rowspan="1" colspan="1">5989</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">60&#x02013;69</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,734,391</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,547,069,498</td><td valign="bottom" align="center" rowspan="1" colspan="1">635,915</td><td valign="bottom" align="center" rowspan="1" colspan="1">61,340</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,753</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">70&#x02013;79</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,559,170</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,762,316,669</td><td valign="bottom" align="center" rowspan="1" colspan="1">284,970</td><td valign="bottom" align="center" rowspan="1" colspan="1">79,674</td><td valign="bottom" align="center" rowspan="1" colspan="1">26,508</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Above 80</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,486,301</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,500,350,138</td><td valign="bottom" align="center" rowspan="1" colspan="1">170,480</td><td valign="bottom" align="center" rowspan="1" colspan="1">103,205</td><td valign="bottom" align="center" rowspan="1" colspan="1">59,116</td></tr><tr><td rowspan="9" valign="middle" align="left" colspan="1">Region</td><td valign="bottom" align="center" rowspan="1" colspan="1">East Midlands</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,842,841</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,923,964,911</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,086,738</td><td valign="bottom" align="center" rowspan="1" colspan="1">41,310</td><td valign="bottom" align="center" rowspan="1" colspan="1">10,572</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">East of England</td><td valign="bottom" align="center" rowspan="1" colspan="1">6,278,538</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,821,826,715</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,296,183</td><td valign="bottom" align="center" rowspan="1" colspan="1">43,192</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,411</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">London</td><td valign="bottom" align="center" rowspan="1" colspan="1">8,837,013</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,309,194,394</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,937,334</td><td valign="bottom" align="center" rowspan="1" colspan="1">67,441</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,285</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">North East</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,651,524</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,599,576,314</td><td valign="bottom" align="center" rowspan="1" colspan="1">638,786</td><td valign="bottom" align="center" rowspan="1" colspan="1">26,268</td><td valign="bottom" align="center" rowspan="1" colspan="1">6407</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">North West</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,420,784</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,455,050,061</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,849,257</td><td valign="bottom" align="center" rowspan="1" colspan="1">78,606</td><td valign="bottom" align="center" rowspan="1" colspan="1">19,004</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">South East</td><td valign="bottom" align="center" rowspan="1" colspan="1">9,264,652</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,678,938,650</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,890,892</td><td valign="bottom" align="center" rowspan="1" colspan="1">59,760</td><td valign="bottom" align="center" rowspan="1" colspan="1">16,179</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">South West</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,680,938</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,491,446,658</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,050,950</td><td valign="bottom" align="center" rowspan="1" colspan="1">28,731</td><td valign="bottom" align="center" rowspan="1" colspan="1">7439</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">West Midlands</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,894,953</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,564,918,434</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,296,108</td><td valign="bottom" align="center" rowspan="1" colspan="1">48,408</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,840</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Yorkshire and the Humber</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,473,167</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,307,600,870</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,264,237</td><td valign="bottom" align="center" rowspan="1" colspan="1">45,367</td><td valign="bottom" align="center" rowspan="1" colspan="1">10,686</td></tr><tr><td rowspan="5" valign="middle" align="left" colspan="1">IMD quintile</td><td valign="bottom" align="center" rowspan="1" colspan="1">IMD1</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,674,923</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,699,769,599</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,569,158</td><td valign="bottom" align="center" rowspan="1" colspan="1">44,322</td><td valign="bottom" align="center" rowspan="1" colspan="1">11,696</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">IMD2</td><td valign="bottom" align="center" rowspan="1" colspan="1">9,445,584</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,762,949,346</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,921,063</td><td valign="bottom" align="center" rowspan="1" colspan="1">63,003</td><td valign="bottom" align="center" rowspan="1" colspan="1">16,629</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">IMD3</td><td valign="bottom" align="center" rowspan="1" colspan="1">10,876,412</td><td valign="bottom" align="center" rowspan="1" colspan="1">6,615,134,330</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,302,369</td><td valign="bottom" align="center" rowspan="1" colspan="1">78,105</td><td valign="bottom" align="center" rowspan="1" colspan="1">20,659</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">IMD4</td><td valign="bottom" align="center" rowspan="1" colspan="1">11,801,363</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,137,336,955</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,586,990</td><td valign="bottom" align="center" rowspan="1" colspan="1">95,823</td><td valign="bottom" align="center" rowspan="1" colspan="1">22,278</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">IMD5</td><td valign="bottom" align="center" rowspan="1" colspan="1">16,546,128</td><td valign="bottom" align="center" rowspan="1" colspan="1">9,937,326,777</td><td valign="bottom" align="center" rowspan="1" colspan="1">3,930,905</td><td valign="bottom" align="center" rowspan="1" colspan="1">157,830</td><td valign="bottom" align="center" rowspan="1" colspan="1">36,561</td></tr><tr><td rowspan="5" valign="middle" align="left" colspan="1">Ethnicity</td><td valign="bottom" align="center" rowspan="1" colspan="1">Asian (other)</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,548,640</td><td valign="bottom" align="center" rowspan="1" colspan="1">913,540,586</td><td valign="bottom" align="center" rowspan="1" colspan="1">322,769</td><td valign="bottom" align="center" rowspan="1" colspan="1">9381</td><td valign="bottom" align="center" rowspan="1" colspan="1">1209</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Black</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,307,809</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,356,279,568</td><td valign="bottom" align="center" rowspan="1" colspan="1">601,101</td><td valign="bottom" align="center" rowspan="1" colspan="1">23,642</td><td valign="bottom" align="center" rowspan="1" colspan="1">3152</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Mixed/other</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,698,916</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,643,470,031</td><td valign="bottom" align="center" rowspan="1" colspan="1">395,571</td><td valign="bottom" align="center" rowspan="1" colspan="1">11,892</td><td valign="bottom" align="center" rowspan="1" colspan="1">1143</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">South Asian</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,058,419</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,381,064,042</td><td valign="bottom" align="center" rowspan="1" colspan="1">984,164</td><td valign="bottom" align="center" rowspan="1" colspan="1">33,238</td><td valign="bottom" align="center" rowspan="1" colspan="1">5381</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">White</td><td valign="bottom" align="center" rowspan="1" colspan="1">45,730,626</td><td valign="bottom" align="center" rowspan="1" colspan="1">27,858,162,780</td><td valign="bottom" align="center" rowspan="1" colspan="1">10,006,880</td><td valign="bottom" align="center" rowspan="1" colspan="1">360,930</td><td valign="bottom" align="center" rowspan="1" colspan="1">96,938</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2.</label><caption><title>Population for England with numbers of first recorded Pillar 2 PCR-confirmed SARS-CoV-2, hospitalizations, and deaths in England between 10 May 2020 and 27 February 2022.</title><p>Breakdown by vaccination status for categories with more than 200,000 doses at the end of the study period (<italic toggle="yes">n</italic> is the count of individuals in this category at the end of the study period, person-days at risk, and counts of Pillar 2 PCR-positive cases, hospitalizations, and deaths are over the entire study period). Vaccination status categories are by vaccination type (adenovirus or mRNA), vaccine dose, and time since vaccination. The whole table is available in fig. S12. w, weeks; d, days.</p></caption><table frame="hsides" rules="groups"><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Variable</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Category</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Person-days at risk</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Cases (Pillar 2 PCR)</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Hospitalizations</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Deaths</th></tr></thead><tbody><tr><td rowspan="16" valign="middle" align="left" colspan="1">Vaccination status</td><td valign="bottom" align="center" rowspan="1" colspan="1">Not vaccinated</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,524,706</td><td valign="bottom" align="center" rowspan="1" colspan="1">21,652,863,421</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,030,900</td><td valign="bottom" align="center" rowspan="1" colspan="1">289,451</td><td valign="bottom" align="center" rowspan="1" colspan="1">80,601</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">First dose &#x0003e; 3 w, adenovirus</td><td valign="bottom" align="center" rowspan="1" colspan="1">343,341</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,168,792,975</td><td valign="bottom" align="center" rowspan="1" colspan="1">97,771</td><td valign="bottom" align="center" rowspan="1" colspan="1">6782</td><td valign="bottom" align="center" rowspan="1" colspan="1">2419</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Second dose over 18 w, adenovirus</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,781,388</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,561,139,076</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,068,220</td><td valign="bottom" align="center" rowspan="1" colspan="1">33,061</td><td valign="bottom" align="center" rowspan="1" colspan="1">5879</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster dose &#x0003c; 2 w, adenovirus</td><td valign="bottom" align="center" rowspan="1" colspan="1">7,434,225</td><td valign="bottom" align="center" rowspan="1" colspan="1">772,914,618</td><td valign="bottom" align="center" rowspan="1" colspan="1">428,088</td><td valign="bottom" align="center" rowspan="1" colspan="1">10,506</td><td valign="bottom" align="center" rowspan="1" colspan="1">966</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster dose &#x0003e; 2 w, adenovirus</td><td valign="bottom" align="center" rowspan="1" colspan="1">9,188,109</td><td valign="bottom" align="center" rowspan="1" colspan="1">332,906,007</td><td valign="bottom" align="center" rowspan="1" colspan="1">137,555</td><td valign="bottom" align="center" rowspan="1" colspan="1">11,487</td><td valign="bottom" align="center" rowspan="1" colspan="1">1522</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster over 18 w, adenovirus</td><td valign="bottom" align="center" rowspan="1" colspan="1">508,392</td><td valign="bottom" align="center" rowspan="1" colspan="1">12,907,790</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,238</td><td valign="bottom" align="center" rowspan="1" colspan="1">661</td><td valign="bottom" align="center" rowspan="1" colspan="1">148</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">First dose &#x0003c; 21 d, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">253,760</td><td valign="bottom" align="center" rowspan="1" colspan="1">438,532,528</td><td valign="bottom" align="center" rowspan="1" colspan="1">210,475</td><td valign="bottom" align="center" rowspan="1" colspan="1">7628</td><td valign="bottom" align="center" rowspan="1" colspan="1">2364</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">First dose &#x0003e; 3 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">2,462,228</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,187,931,423</td><td valign="bottom" align="center" rowspan="1" colspan="1">542,990</td><td valign="bottom" align="center" rowspan="1" colspan="1">8482</td><td valign="bottom" align="center" rowspan="1" colspan="1">2388</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Second dose &#x0003c; 2 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">331,407</td><td valign="bottom" align="center" rowspan="1" colspan="1">234,175,466</td><td valign="bottom" align="center" rowspan="1" colspan="1">47,748</td><td valign="bottom" align="center" rowspan="1" colspan="1">627</td><td valign="bottom" align="center" rowspan="1" colspan="1">66</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Second dose &#x0003e; 2 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,206,396</td><td valign="bottom" align="center" rowspan="1" colspan="1">829,053,400</td><td valign="bottom" align="center" rowspan="1" colspan="1">113,626</td><td valign="bottom" align="center" rowspan="1" colspan="1">1686</td><td valign="bottom" align="center" rowspan="1" colspan="1">132</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Second dose 10&#x02013;18 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">967,000</td><td valign="bottom" align="center" rowspan="1" colspan="1">919,526,650</td><td valign="bottom" align="center" rowspan="1" colspan="1">373,924</td><td valign="bottom" align="center" rowspan="1" colspan="1">4419</td><td valign="bottom" align="center" rowspan="1" colspan="1">398</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Second dose over 18 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">4,066,262</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,129,558,164</td><td valign="bottom" align="center" rowspan="1" colspan="1">751,049</td><td valign="bottom" align="center" rowspan="1" colspan="1">18,615</td><td valign="bottom" align="center" rowspan="1" colspan="1">3765</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster 10&#x02013;18 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">301,068</td><td valign="bottom" align="center" rowspan="1" colspan="1">178,424,050</td><td valign="bottom" align="center" rowspan="1" colspan="1">168,635</td><td valign="bottom" align="center" rowspan="1" colspan="1">1738</td><td valign="bottom" align="center" rowspan="1" colspan="1">151</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster dose &#x0003c; 2 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">6,054,894</td><td valign="bottom" align="center" rowspan="1" colspan="1">586,137,083</td><td valign="bottom" align="center" rowspan="1" colspan="1">294,073</td><td valign="bottom" align="center" rowspan="1" colspan="1">7356</td><td valign="bottom" align="center" rowspan="1" colspan="1">770</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster dose &#x0003e; 2 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">5,512,367</td><td valign="bottom" align="center" rowspan="1" colspan="1">326,242,322</td><td valign="bottom" align="center" rowspan="1" colspan="1">207,494</td><td valign="bottom" align="center" rowspan="1" colspan="1">14,032</td><td valign="bottom" align="center" rowspan="1" colspan="1">1809</td></tr><tr><td valign="bottom" align="center" rowspan="1" colspan="1">Booster over 18 w, mRNA</td><td valign="bottom" align="center" rowspan="1" colspan="1">1,954,193</td><td valign="bottom" align="center" rowspan="1" colspan="1">43,244,152</td><td valign="bottom" align="center" rowspan="1" colspan="1">16,974</td><td valign="bottom" align="center" rowspan="1" colspan="1">2059</td><td valign="bottom" align="center" rowspan="1" colspan="1">385</td></tr></tbody></table></table-wrap><p>We examined a total of 360 model variants, which varied by the covariates and interactions included (see section A.2 for covariate definitions considered): age, definition of deprivation, regional disaggregation, ethnicity disaggregation, and which interaction terms to include in the model. Figures S2 to S4 list the top 88 selected models for each outcome of interest. Restriction levels are based on individual policy measures, such as school closure or gathering restrictions, at each time point (sections A and C.3 and figs. S7 to S9). We found that less granular age categories had better 10-fold cross-validation performance (under 40s, 10-year age bands up to 70, single group for 80+). Similarly, coarse spatial disaggregation [by National Health Service (NHS) region of England] was favored, and deprivation was quantified by IMD quintiles. We disaggregated ethnicity into five groups as the results were very similar for the range of ethnicity categorizations examined. The preferred model included covariates for sex, age, NHS region, vaccine status, IMD quintile, ethnicity, and restriction level.</p><p>We compared the estimates from the preferred model against the data and found a good qualitative fit examining marginal incidence rate ratios (IRRs) (fig. S1).</p><p>We investigated the impact of overdispersion for each outcome of interest using negative binomial regression models. For Pillar 2 PCR-confirmed cases, we found a moderate level of overdispersion (<italic toggle="yes">k</italic> = 0.33) during the wild-type period. We found that either very high values of <italic toggle="yes">k</italic> (indicating marginal overdispersion) or the Poisson model was preferred for all other periods. For hospitalization and death outcomes, the Poisson model was always preferred (section A and table S1).</p><p><xref rid="F2" ref-type="fig">Figure 2</xref> presents the modeled IRRs for deprivation and ethnicity categories from the preferred model for each endpoint and by period defined by variant dominance. IRRs for sex, age, and region are presented in fig. S13.</p><fig position="float" id="F2" fig-type="image" specific-use="distribute"><label>Fig. 2.</label><caption><title>Estimated deprivation and ethnicity IRRs. </title><p>Estimated IRRs for (<bold>A</bold>) deprivation and (<bold>B</bold>) ethnicity covariates from preferred models. Deprivation was categorized by quintiles of the IMD score defined at the LTLA level (results for subcomponents are available in the Supplementary Materials), with the first (least deprived) quintile (IMD1) being the reference group (IRR = 1). Results are shown for the whole pandemic (&#x0201c;All&#x0201d;: test dates between May 2020 and February 2022) and for the time intervals within that period where specific viral variants dominated (see the Supplementary Materials for details). WT, wild type (pre&#x02013;December 2020).</p></caption><graphic xlink:href="sciadv.adu8678-f2" position="float"/></fig><p>When we consider the entire period (May 2020 to February 2022), the highest IMD quintile, corresponding to the most deprived LTLAs, has an IRR (relative to the least deprived IMD quintile) of 1.64 [95% confidence interval (CI), 1.60 to 1.67] for death as the outcome, 1.53 (95% CI, 1.51 to 1.55) for hospitalization, and 1.02 (95% CI, 1.02 to 1.02) for a positive Pillar 2 PCR test. For the Pillar 2 positive test outcome, we observed substantial differences between periods defined by variant dominance. The biggest differences were observed for the Alpha variant with an IRR (for the highest quintile relative to the lowest) for that endpoint of 1.45 (95% CI, 1.45 to 1.46).</p><p>For deaths, over the entire study period, South Asian ethnicity had an IRR of 1.63 (95% CI, 1.59 to 1.68), Asian (other) ethnicity an IRR of 1.24 (95% CI, 1.17 to 1.32), and Black ethnicity an IRR of 1.49 (95% CI, 1.43 to 1.54), with white ethnicity as the reference. For hospitalization, over the entire study period, South Asian ethnicity had an IRR of 1.42 (95% CI, 1.40 to 1.44), Asian (other) ethnicity an IRR of 1.17 (95% CI, 1.15 to 1.20), and Black ethnicity an IRR of 1.56 (95% CI, 1.53 to 1.58). Using Pillar 2 PCR-positive tests as the endpoint, over the entire study period, South Asian ethnicity had an IRR of 0.89 (95% CI, 0.88 to 0.89), Asian (other) ethnicity an IRR of 0.78 (95% CI, 0.78 to 0.79), and Black ethnicity an IRR of 0.89 (95% CI, 0.89 to 0.90). The IRRs for mixed/other ethnicity are reported in table S4.</p><p>Ethnicity differences declined for the Pillar 2 PCR-positive test endpoint throughout the pandemic. IRR for Pillar 2 PCR-positive cases declines for all non-white ethnicities (relative to white) over time, with IRR<sub>WT</sub> &#x0003e; IRR<sub>Alpha</sub> &#x0003e; IRR<sub>Delta</sub>. During the Omicron period, non-white IRRs were broadly similar to those during the Delta period but typically slightly above IRR<sub>Delta</sub>. For death, we observed a declining IRR over time for South Asian ethnicity, with IRR<sub>WT</sub>, IRR<sub>Alpha</sub>, and IRR<sub>Delta</sub> exhibiting overlapping CIs but IRR<sub>Omicron</sub> statistically significantly lower. For hospitalization, we observed a declining IRR over time for South Asian ethnicity, with IRR<sub>WT</sub>, IRR<sub>Alpha</sub>, IRR<sub>Delta</sub>, and IRR<sub>Omicron</sub> statistically significantly lower than in the previous period. Other Asian ethnicities had high IRRs (overlapping CIs) for the WT and Alpha periods and significantly lower IRRs for Delta and Omicron. Black ethnicities exhibited high IRRs up to Omicron in the range of 1.38 to 1.45 for death and of 1.16 to 1.87 for the entire period for hospitalization.</p><p>Results for deprivation were consistent for severe outcomes (hospitalization and death) throughout the pandemic, with IRRs monotonically increasing as deprivation increased, but with IRRs during the Omicron period lower than other periods. This result also applied to a more granular representation of deprivation, using deciles (fig. S15) and for the different subcomponents of the IMD measure (figs. S22 to S28). For Pillar 2 PCR-positive cases, we observed an increasing IRR with increasing deprivation for the WT and Alpha periods, but not for the Delta and Omicron periods. This resulted in the IRR for the whole period being close to 1. This result was consistent with IMD deciles and the subcomponents of the IMD index.</p><p><xref rid="F3" ref-type="fig">Figure 3</xref> presents our VE estimates (section B.3 and table S3) for our preferred model. We obtain a VE (defined as 1-IRR) estimate for mRNA vaccines ranging from 86.8% (over 18 weeks after the second dose; 95% CI, 86.2 to 87.3) to 97.1% (less than 2 weeks after the booster dose; 95% CI, 96.6 to 97.6) for protection against death for individuals with at least two doses, from 84.8% (over 18 weeks after second dose; 95% CI, 84.5 to 85.0) to 93.3% (2 to 10 weeks after booster dose; 95% CI, 93.1 to 93.5) against hospitalization, and from 30.4% (over 18 weeks after booster dose; 95% CI, 29.3 to 31.5) to 84.5% (2 to 10 weeks after second dose; 95% CI, 84.4 to 84.6) against Pillar 2 PCR-positive confirmed infections for the full study period.</p><fig position="float" id="F3" fig-type="image" specific-use="distribute"><label>Fig. 3.</label><caption><title>Vaccine effectiveness (VE = 1-IRR) for different vaccination statuses with not vaccinated as the reference group (IRR = 1/VE = 0).</title><p>Results are shown for the whole pandemic (&#x0201c;All&#x0201d;: test dates between May 2020 and February 2022) and for the time intervals within that period where specific viral variants dominated (see the Supplementary Materials for details). Results for the second dose and booster dose categories are displayed for mRNA and adenovirus vaccines (all other results are in table S3 and fig. S14). WT, wild type (pre&#x02013;December 2020). w, weeks.</p></caption><graphic xlink:href="sciadv.adu8678-f3" position="float"/></fig><p>For adenovirus-based vaccines, we estimated VE for individuals with at least two doses, ranging from 77.2% (over 18 weeks after second dose; 95% CI, 76.2 to 78) to 95.9% (less than 2 weeks after booster dose; 95% CI, 95.3 to 96.5) for protection against death, from 78.5% (over 18 weeks after second dose; 95% CI, 78.2 to 78.8) to 94.1% (2 to 10 weeks after booster dose; 95% CI, 94.0 to 94.3) against hospitalization, and from 29.6% (over 18 weeks after booster dose; 95% CI, 27.6 to 31.5) to 68.5% (2 to 10 weeks after second dose; 95% CI, 68.3 to 68.6) against Pillar 2 PCR-positive confirmed infections for the full study period.</p><p>We found that VE was consistently lower for the Omicron period. There was little to no difference in VE estimates for severe outcomes for the Alpha and Delta time periods.</p><p>We present the estimated VE results for all variants, vaccine status, and vaccine types in table S3 with their associated 95% CIs. The CIs are narrow due to the large number of events observed (<xref rid="T2" ref-type="table">Table 2</xref>); CIs are wider for the variant period-specific estimates. A comparison with previous VE estimates is included in section D.2.</p><p><xref rid="F4" ref-type="fig">Figure 4</xref> shows the estimated VE results obtained from an extension of the preferred model, which included an additional interaction term between vaccine status and IMD quintile. Panel (A) presents results for the period when Delta was the dominant variant, while panel (B) covers Omicron. For deaths and hospitalizations, we did not observe significant differences in VE between IMD quintiles, except for the period over 18 weeks post&#x02013;second dose during the Delta phase for deaths, where there was a tendency for the least deprived areas (IMD 1 and 2) to have lower VE than the more deprived areas (IMD 4 and 5).</p><fig position="float" id="F4" fig-type="image" specific-use="distribute"><label>Fig. 4.</label><caption><title>Vaccine effectiveness (VE = 1-IRR) for the preferred model with an additional interaction term for vaccine status and IMD, with not vaccinated as the reference group (IRR = 1/VE = 0).</title><p>Results are shown for the Delta period (<bold>A</bold>) and Omicron period (<bold>B</bold>), and results for the second dose and booster dose categories are displayed for mRNA and adenovirus. w, weeks.</p></caption><graphic xlink:href="sciadv.adu8678-f4" position="float"/></fig><p>For PCR-confirmed infections, we found different results for the Delta and Omicron periods. During Delta, we typically observed the ordering of IMD quintiles was higher VE for less deprived areas than more deprived areas, particularly less than 18 weeks since the second dose. VE estimates cluster together for over 18 weeks since the second and booster doses. For Omicron, we observed little variability in VE by IMD for second and booster doses, but VE estimates were higher for less deprived areas. The exception is for over 18 weeks since the booster dose, for which we observed higher VE for more deprived areas. Results for IRRs of all covariates for the model with an interaction term between vaccine status and IMD quintile are presented in fig. S19 and for vaccine status and ethnicity in fig. S20.</p><p><xref rid="F5" ref-type="fig">Figure 5</xref> shows the estimated IRRs for the restriction level covariate for our preferred model. The IRRs for restriction levels were robust to regional resolution, up to and including the LTLA level (figs. S17 and S18). We estimated the IRR for restriction level over the full study period of 1.14 (95% CI, 1.12 to 1.15) for deaths, 1.15 (95% CI, 1.14 to 1.16) for hospitalization, and 1.17 (95% CI, 1.17 to 1.17) for Pillar 2 PCR-positive cases. These estimates indicate that periods of high levels of public health restrictions were associated with higher levels of risk than periods where restriction levels were lower. The estimated IRR for restriction level for the WT and Alpha periods was lower for deaths and hospitalization than for the full-time period, which includes longer time intervals with no restrictions. However, for Pillar 2 PCR-confirmed infections, we found that the IRR for restriction level was higher during the WT period and lower for the Alpha period than for the full-time period (<xref rid="F5" ref-type="fig">Fig. 5</xref>). The IRRs for the Delta and Omicron periods are one, as no substantial restrictions were in place over those periods.</p><fig position="float" id="F5" fig-type="image" specific-use="distribute"><label>Fig. 5.</label><caption><title>Estimated IRRs for restriction levels.</title><p>Results are shown for the whole pandemic (&#x0201c;All&#x0201d;: test dates between May 2020 and February 2022) and for the time intervals within that period where specific viral variants dominated (see the Supplementary Materials for details). Restriction level is a numeric covariate in the model.</p></caption><graphic xlink:href="sciadv.adu8678-f5" position="float"/></fig></sec><sec sec-type="discussion" disp-level="1"><title>DISCUSSION</title><p>We considered the impact of sex, age, region, deprivation, level of restrictions, and ethnicity on the relative risk of a SARS-CoV-2 Pillar 2 PCR-positive first recorded infection, hospitalization, or death. Our proposed model was selected to provide a good fit across all three outcomes of interest. Our results extend previous work on the impact of deprivation (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>) and evidence risk heterogeneity by ethnicity in England (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>, <xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>, <xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>) and globally (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>, <xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>).</p><p>We find that modeling overdispersion for Pillar 2 PCR-positive cases was necessary for the wild-type period, consistent with (<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>), and the value for the overdispersion that we find aligns with other estimates outside China (<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>, <xref rid="R30" ref-type="bibr"><italic toggle="yes">30</italic></xref>). We did not find overdispersion to be present for severe outcomes, and the Poisson model provides the best fit to the data. Although Pillar 2 PCR tests were available widely, this indicates that some groups, defined by higher levels of deprivation or non-white ethnicity, may have accessed testing less, leading to the observed overdispersion. This was less likely to be the case for more severe outcomes as testing would be more likely conducted due to the more severe nature of the infection.</p><p>The differences in IRRs we observe by outcome (PCR-confirmed infection, hospitalization, or death) indicate a difference between severe outcomes and infections. For severe outcomes, we observed a significant risk heterogeneity by age, with older age groups at higher risks than younger age groups at an exponential rate (fig. S13B) consistent with the variation of the infection fatality ratio by age in the pre-vaccination era (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). Increased risk was also positively associated with higher levels of deprivation (<xref rid="F2" ref-type="fig">Fig. 2A</xref>), and the difference between the most deprived quintile of LTLAs and the least deprived quintile was significant for all periods considered. Similarly, we found that non-white ethnicities were at increased risk.</p><p>For Pillar 2 PCR-positive cases, the picture is more nuanced. We observed that the differences in risk between age groups were of a similar magnitude as the large differences that we observed for severe outcomes. These differences are consistent with past studies and may reflect age-specific self-protective behaviors (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>) and/or variation in contact rates [fig. S8, (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>)]. For deprivation and ethnicity, risk heterogeneity was similar in trends as for more severe outcomes, but the magnitude of differences was less. The results for Pillar 2 PCR-positive cases were consistent with other studies (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>, <xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>).</p><p>For severe outcomes, we observed less variation in deprivation- or ethnicity-related risk differences across the course of the pandemic, pointing to existing health inequalities driving the strong association between deprivation, ethnicity, and risk of severe outcomes. This held consistently for all subcomponents of the IMD, except for the living environment component, and particularly strongly for the income, employment, health, and education subcomponents (figs. S22 to S28). This observation is consistent with known socioeconomic and ethnic disparities in the UK for type 2 diabetes (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>), which is a known risk factor for severe SARS-CoV-2 infection outcomes. We observed a high IRR for South Asian ethnicity, for both severe outcomes and infections, which reduced over time (<xref rid="F2" ref-type="fig">Fig. 2B</xref>), perhaps suggesting the metabolic component impacting outcomes being reduced for omicron and delta as individuals of South Asian ethnicity are at higher risk of metabolic disease (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>).</p><p>We assessed VE, and our results broadly align with previously published VE estimates for England by the UK Health Security Agency (UKHSA) (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>) for similar periods and VE definitions. We find VE for the mRNA vaccines is consistent with UKHSA estimates of 88.0% (95% CI, 85.3 to 90.1) for two doses of BNT162b2 for infections for persons with the Delta variant. Similarly, we find VE for the adenovirus vaccines is in line with UKHSA estimates of 67.0% (95% CI, 61.3 to 71.8) for persons with two doses of the ChAdOx1 nCoV-19 vaccine. For the Omicron variant, estimates vary more widely (<xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>) with VE against hospitalization, ranging from 50.5 to 89.2%, broadly consistent with 67.8 to 92.4% from the literature. Similarly, VE against Pillar 2 PCR-confirmed infection ranging from 17 to 69.5% compared to 11.7 to 75.3% in the literature. We note that we only consider the first recorded infections for the Omicron period, which may bias our VE estimates to be higher, which is offset by our longer study period.</p><p>We considered VE stratified by deprivation (<xref rid="F4" ref-type="fig">Fig. 4</xref>). For Pillar 2 infections, observed differences in VE may be explained by differences in the propensity to seek testing, which was associated with both deprivation level and vaccination status. Later in the pandemic, the propensity to seek testing was substantially lower in the most deprived areas than the least deprived (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). Higher VE for the least deprived areas might also be due to higher levels of infection-induced immunity in more deprived areas; if mild infections were less likely to be detected in more deprived areas, then the unvaccinated group would have higher immunity levels, resulting in lower VE estimates for the most deprived IMD quintile.</p><p>The policy implications of our study are that both protective and support measures need to be structured with ethnicity and deprivation in mind, particularly in the early stages of a pandemic. Deprivation had a particularly significant impact during the Alpha variant era for PCR-confirmed infections. For ethnicity, we observed a reduction in IRRs as the pandemic progressed (<xref rid="F3" ref-type="fig">Fig. 3</xref>). This suggests that more deprived areas were less able to isolate effectively, potentially due to work, during heightened public health restrictions. Ethnic minorities were more likely to work in occupations where workplace attendance continued even during lockdowns and also had less access to savings (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>), potentially exposing them to a higher risk of community transmission. This is particularly true for Bangladeshi and Pakistani men working in the hospitality, leisure, and transport sectors. South Asian and African-Black men are also overrepresented in health and social care roles in England, potentially leading to higher levels of infection risk during the pandemic (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>).</p><p>Considering the impact of the public health restriction level, we found IRRs &#x0003e; 1 for all outcomes in the wild-type and Alpha periods. Restrictions were highest during periods of high hospitalization and death incidence (fig. S10). The higher IRR for deaths during Alpha, relative to wild type, was consistent with the hospitalization fatality ratio being higher for Alpha than wild type (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>). The IRR for deaths over the entire study period was comparable to the IRR for deaths during Alpha, suggesting that vaccination during Delta and Omicron, both periods of low to no restrictions, contributed to lower risk relative to wild type and Alpha. We find an IRR greater than one for hospitalizations but higher IRRs during wild type than Alpha. Similarly to deaths, we find the highest IRRs for the entire study period, pointing to the impact of vaccination in the second half of the study period. For Pillar 2 PCR cases, we observe an IRR greater than one, with IRRs highest during wild type. The IRRs for the full study period are lower than for wild type, as we observed substantial infections in both the unvaccinated and vaccinated groups during Omicron, a period with no restrictions. We note that this IRR for the entire study period would be lower if we had taken lateral flow tests (LFTs) into account.</p><p>This highlights the impact of the different timing of restrictions between regions, as we already account for week and region effects in the model. We note that other results were not sensitive to whether restrictions were included as a predictor in the model, and the IRRs for restrictions were robust to different resolutions of the regional covariate.</p><p>A limitation is that we only considered first recorded infections in this study and did attempt to investigate reinfections. However, we note that, up to November 2021, with the arrival of the Omicron variant of SARS-CoV-2, 93% of all recorded infections were first infections. In addition, we only quantify incidence among those seeking tests, not underlying infection incidence. This may affect our results if the propensity to seek a test varied by age, deprivation, or ethnicity, especially if underlying true infection incidence varied substantially by those variables. Hence, for the Pillar-2 test outcome, risk and VE differences between population groups/strata may reflect true exposure differences, differences in propensity to seek a test, or both. Such considerations do not affect the hospitalization and death endpoints, as testing was universal for anyone entering hospital for the large majority of the study period. For Omicron, we only consider PCR test results and do not include LFTs.</p><p>Future research priorities include a multi-outcome survival model to incorporate infections and severe outcomes in the same model. Integrating serology and infection prevalence data is essential in addressing questions such as the impact of preexisting comorbidities on the risk heterogeneity by ethnicity or socioeconomic group.</p></sec><sec sec-type="materials|methods" disp-level="1"><title>MATERIALS AND METHODS</title><sec disp-level="2"><title>Data sources</title><p>UKHSA maintains a single unified database of all SARS-CoV-2&#x02013;positive test results in the country, categorized by pillar. The resulting database contains a hashed version of a unique identifier (NHS number), the age, sex, ethnic group, home LTLA, symptom status, testing pillar, and date of specimen for each positive case.</p><p>Second, linked to the case database by (hashed) NHS number, UKHSA maintains a database of all deaths within 28 days of a positive PCR test for SARS-CoV-2. This database records the date of death, the date of hospital admission, and how the death was identified (e.g., via hospital reporting, death registration, or both).</p><p>Third, two NHS data sources on hospitalization were also linked by NHS number to the case database: the Secondary Uses Service data on hospital episodes and the Emergency Care Data Set on attendance at Accident and Emergency departments. An individual in these datasets was classified as hospitalized with COVID-19 if they had a positive PCR test between 14 days before admission and the day before discharge, and they were classified as an inpatient.</p><p>Last, England maintains a national vaccination register, the National Immunization Management System (NIMS) (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Every SARS-CoV-2 vaccine dose given in England is recorded at the time of vaccine administration. The anonymized version of the dataset used here contained a unique identifier (hashed NHS number), age, sex, ethnic group, LTLA, and administration date.</p><p>We extracted data from the versions of these databases with data up to 25 July 2023. Cases with a valid NHS number were then linked to the NIMS vaccination dataset. Where a match was found, the case was classified as having received a vaccine (either before or after testing positive). Cases with no matching immunization record were classified as having not been vaccinated. In our analysis, we used the vaccination status of an individual at the time of testing. The vaccination status includes the type of vaccine, number of doses received, and time since the last vaccination.</p><p>PCR testing (Pillars 1 and 2) was initially focused on key workers in the NHS, social care, and other sectors due to limited testing capacity. From May 2020, testing was widened to individuals with symptoms in the general public, and regular asymptomatic testing of individuals working in high-risk settings, such as care homes, was introduced (<xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>). Individuals with a positive SARS-CoV-2 test were initially advised to self-isolate for 14 days, with subsequent rules being more complex and dependent on testing (fig. S9). Limited support was available to individuals who had to self-isolate, provided that they met several criteria, such as not being able to work at home and being in receipt of at least one state benefit (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>).</p><p>Population denominator data were used to calculate the number of people who neither have received a vaccine nor have been diagnosed with SARS-CoV-2 infection. We used the Census 2021 population estimates generated by the ONS (<xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>), stratified by age, sex, and LTLA (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>). We made the simplifying assumption that, in the absence of COVID-19, the size of the English population and its age distribution would have been at a steady state for our analysis period consistent with the Census 2021 estimates. Individuals with missing information on sex, age, or residence location were not included in the analysis.</p><p>We use the IMD dataset released in 2019 (<xref rid="R12" ref-type="bibr"><italic toggle="yes">12</italic></xref>) by the UK Ministry of Housing, Local Communities, and Local Government, aggregated at the LTLA level and its subcomponents (section B.4).</p><p>The public health and social restriction level was computed from ONS LTLA data up to December 2020 (<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>) and the Oxford COVID-19 Government Response Tracker (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>) (sections A and C.3). Several non-pharmaceutical interventions were used across the course of the pandemic, including containment, school closure, and stay-at-home orders. The &#x0201c;roadmap out of lockdown&#x0201d; policy in spring 2021 had three intermediate steps between national lockdown and no restrictions. We mapped the restrictions over time onto a five-level scale based on the individual policy measures in place at each time point (section C.3).</p></sec><sec disp-level="2"><title>Statistical analysis</title><p>Survival models were used to estimate IRRs, an estimate of the increased risk of a particular outcome for a specific population group relative to a reference group. We used Poisson regression using an offset to adjust for person-days at risk to generate IRRs for the different strata of interest, proving a good approximation to continuous time survival models (section A) (<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>). Poisson regressions are more general than Cox proportional hazard survival models, allowing for nonproportional hazards. We investigated using negative binomial regressions to account for overdispersion. We parametrically captured variation by systematically examining evidence for interactions between covariates. We conducted model selection to identify the model which performed best across all three outcomes of interest (infection, hospitalization, and deaths) by considering the average Akaike&#x02019;s information criterion and coefficient of determination (<italic toggle="yes">R</italic><sup>2</sup>) (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>, <xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>) across the three respective models.</p><p>We included terms for sex, ethnic group, vaccination status, and IMD in all models. We used a categorical IMD variable, ranking LTLAs by average IMD score and then binning them into quintiles (1 being least deprived and 5 being most). The four other covariates included in all models were geographic region (either upper tier local authority or region), age (in 10-year bands with the last band being 85+ or 10-year bands with all individuals below 40 grouped and a maximum age of 80+), restriction levels (used as a parametric covariate as restriction levels changed several times, creating non-continuous time intervals), and epidemiological week. We examined all pairwise interactions between these three variables. The combined restriction covariate was also included in the preferred model.</p><p>All survival analyses used the test specimen date as the outcome event date. Three SARS-CoV-2-related events were defined: death within 28 days of any positive PCR test, hospitalization where the individual hospitalized tested PCR-positive between 14 days before admission and the day before discharge and was classed as an inpatient, and any PCR-confirmed infection within Pillar 2. We only consider the first recorded SARS-CoV-2 infection for all three events and associated hospitalizations and deaths.</p><p>We fitted the model for all three outcomes of interest. Individuals were treated as censored after a positive SARS-CoV-2 PCR test to exclude postprimary infections and avoid bias because the UK vaccination program excluded people from being vaccinated within 28 days of a positive test.</p><p>Because the UKHSA/NHS and ONS data used different ethnicity categories, we aggregated ethnicities into five groups that could be identified consistently across all datasets: white, South Asian, Asian (other), Black, and mixed/other to be consistent across two datasets (section B.1). Details are provided in the Supplementary Materials (section B.1). The computation of age for each individual is outlined in section B.2.</p><p>We estimated VE accounting for the type of vaccine (mRNA or adenovirus based), time since vaccination, and outcome of interest (death, hospitalization, and Pillar 2 PCR-positive case). Details are provided in section B.3. By comparing now vaccinated individuals against people who would be vaccinated in the future, we controlled for potential differences in behavior and exposure risk between those who are never vaccinated and those who eventually are. Censoring after the first recorded positive test partially mitigated estimates from being affected by the accumulation of naturally acquired immunity in the population.</p><p>To investigate how estimates varied over time, for example, in periods dominated by particular variants, we restricted model fitting to data from the specific period of interest (censoring individuals with positive tests before that period).</p><p>We used negative binomial regressions as a sensitivity analysis to explore overdispersion in the count data. In all figures, we display only results with a <italic toggle="yes">P</italic> value of 0.05 or less.</p><p>Interactions between VE and deprivation were examined by running the preferred model with an additional interaction term for vaccine status and IMD. Similarly, we investigated associations between VE and any ethnicity by running the preferred model with an interaction term for vaccine status and ethnicity.</p><p>All analyses were undertaken in R version 4.3.1 using the H2O.ai machine learning package version 3.42.0.2 (<xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>), which offers high-performance parallelized algorithms for fitting general linear models to large datasets. A 32-core Intel-based server with 128-GB RAM was used to conduct the analyses.</p></sec><sec disp-level="2"><title>Ethics statement</title><p>Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (<ext-link xlink:href="http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made" ext-link-type="uri">www.legislation.gov.uk/uksi/2002/1438/regulation/3/made</ext-link>) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii), and 3(3). Data were shared with the investigators as part of the UK&#x02019;s emergency response to the COVID-19 pandemic via the SPI-M subcommittee of the UK Scientific Advisory Group for Emergencies. Ethics permission was sought for the study via Imperial College London&#x02019;s standard ethical review processes, and the study was approved by the College&#x02019;s Research Governance and Integrity Team (ICREC reference: 21IC6945).</p></sec></sec></body><back><ack><title>Acknowledgments</title><p><bold>Funding:</bold> We acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research Protection Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency (UKHSA), Imperial College London, and London School of Hygiene &#x00026; Tropical Medicine (grant code NIHR200908); and a philanthropic donation from Community Jameel supporting the work of the Jameel Institute. S.B. acknowledges support from the Novo Nordisk Foundation via The Novo Nordisk Young Investigator Award (NNF20OC0059309). S.B. acknowledges the Danish National Research Foundation (DNRF160) through the chair grant. S.B. acknowledges support from Schmidt Sciences via the Schmidt Polymath Award (G-22-63345), which also supports C.M. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. </p><sec><p><bold>Author contributions:</bold> Conceptualization: N.M.F., C.M., and S.B. Data curation: C.M., W.H., and P.N.P.G. Formal analysis: C.M. and N.M.F. Funding acquisition: N.M.F. and S.B. Investigation: C.M., N.M.F., and S.B. Methodology: C.M., T.R., S.B., and N.M.F. Project administration: C.M., N.M.F., and S.B. Resources: C.M., N.M.F., and S.B. Software: C.M., W.H., and N.M.F. Supervision: N.M.F. and S.B. Validation: C.M., P.N.P.G., N.M.F., and S.B. Visualization: C.M. and S.B. Writing&#x02014;original draft: C.M., N.M.F., and S.B. Writing&#x02014;review and editing: C.M., T.R., S.B., and N.M.F. All authors discussed, edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to submit the manuscript for publication.</p></sec><sec><p><bold>Competing interests:</bold> P.N.P.G. has performed paid consulting for Pfizer and Munich Re in matters related to pandemic modeling; neither entity had any form of involvement in the present study. The authors declare that they have no other competing interests.</p></sec><sec><p><bold>Data and materials availability:</bold> While all data used in this analysis were anonymized, the individual-level nature of the data used risks individuals being identified or being able to self-identify if it is released publicly. Requests for access to the underlying source data should be directed to UKHSA. The access to protected data request is available at <ext-link xlink:href="http://www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-ukhsa-protected-data" ext-link-type="uri">www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-ukhsa-protected-data</ext-link>. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Codes are available in Github (<ext-link xlink:href="https://github.com/cm401/covid19_risk_heterogeneity_england" ext-link-type="uri">https://github.com/cm401/covid19_risk_heterogeneity_england</ext-link>) and Zenodo (<ext-link xlink:href="https://doi.org/10.5281/zenodo.15202350" ext-link-type="uri">https://doi.org/10.5281/zenodo.15202350</ext-link>).</p></sec></ack><sec sec-type="supplementary-material"><title>Supplementary Materials</title><sec><title>This PDF file includes:</title><supplementary-material position="float" content-type="local-data"><caption><p>Sections A to E</p><p>Figs. S1 to S28</p><p>Tables S1 to S6</p><p>References</p></caption><media xlink:href="sciadv.adu8678_sm.pdf"/></supplementary-material></sec></sec><ref-list><title>REFERENCES AND NOTES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Hale</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Angrist</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Goldszmidt</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Kira</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Petherick</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Phillips</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Webster</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameron-Blake</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Hallas</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Majumdar</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Tatlow</surname></string-name></person-group>, 
<article-title>A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)</article-title>. <source>Nat. Hum. Behav.</source>
<volume>5</volume>, 
<fpage>529</fpage>&#x02013;<lpage>538</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33686204</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="webpage">T. Phillips, A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker), GitHub (2023); <ext-link xlink:href="https://github.com/OxCGRT/covid-policy-dataset" ext-link-type="uri">https://github.com/OxCGRT/covid-policy-dataset</ext-link>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Kontopantelis</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Mamas</surname></string-name>, <string-name><given-names>R. T.</given-names>
<surname>Webb</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Castro</surname></string-name>, <string-name><given-names>M. K.</given-names>
<surname>Rutter</surname></string-name>, <string-name><given-names>C. P.</given-names>
<surname>Gale</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Ashcroft</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pierce</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Abel</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Price</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Faivre-Finn</surname></string-name>, <string-name><given-names>H. G. C.</given-names>
<surname>Van Spall</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Morciano</surname></string-name>, <string-name><given-names>G. P.</given-names>
<surname>Martin</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Doran</surname></string-name></person-group>, 
<article-title>Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study</article-title>. <source>Lancet Reg. Health Eur.</source>
<volume>7</volume>, 
<fpage>100144</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34557845</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Atchison</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Whitaker</surname></string-name>, <string-name><given-names>K. E. C.</given-names>
<surname>Ainslie</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Elliott</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Okell</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Redd</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Ashby</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Donnelly</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Barclay</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Darzi</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Cooke</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Elliott</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>905</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33568663</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V. J.</given-names>
<surname>McGowan</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Bambra</surname></string-name></person-group>, 
<article-title>COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities</article-title>. <source>Lancet Public Health</source>
<volume>7</volume>, 
<fpage>e966</fpage>&#x02013;<lpage>e975</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36334610</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.-H.</given-names>
<surname>Lo</surname></string-name>, <string-name><given-names>L. H.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Drew</surname></string-name>, <string-name><given-names>E. T.</given-names>
<surname>Warner</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Joshi</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Anyane-Yeboa</surname></string-name>, <string-name><given-names>F. M.</given-names>
<surname>Shebl</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Astley</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Figueiredo</surname></string-name>, <string-name><given-names>C.-G.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Mehta</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kwon</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Davies</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Capdevila</surname></string-name>, <string-name><given-names>C. H.</given-names>
<surname>Sudre</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wolf</surname></string-name>, <string-name><given-names>Y. C.</given-names>
<surname>Cozier</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rosenberg</surname></string-name>, <string-name><given-names>L. R.</given-names>
<surname>Wilkens</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Haiman</surname></string-name>, <string-name><given-names>L. L.</given-names>
<surname>Marchand</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Palmer</surname></string-name>, <string-name><given-names>T. D.</given-names>
<surname>Spector</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ourselin</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Steves</surname></string-name>, <string-name><given-names>A. T.</given-names>
<surname>Chan</surname></string-name>, <collab>COPE Consortium</collab></person-group>, 
<article-title>Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom</article-title>. <source>EClinicalMedicine</source>
<volume>38</volume>, 
<fpage>101029</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34308322</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Pan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sze</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Minhas</surname></string-name>, <string-name><given-names>M. N.</given-names>
<surname>Bangash</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Pareek</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Divall</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Williams</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Oggioni</surname></string-name>, <string-name><given-names>I. B.</given-names>
<surname>Squire</surname></string-name>, <string-name><given-names>L. B.</given-names>
<surname>Nellums</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Hanif</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Khunti</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pareek</surname></string-name></person-group>, 
<article-title>The impact of ethnicity on clinical outcomes in COVID-19: A systematic review</article-title>. <source>EClinicalMedicine</source>
<volume>23</volume>, 
<fpage>100404</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32632416</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Mathur</surname></string-name>, <string-name><given-names>C. T.</given-names>
<surname>Rentsch</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>Morton</surname></string-name>, <string-name><given-names>W. J.</given-names>
<surname>Hulme</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Schultze</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>MacKenna</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Eggo</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Bhaskaran</surname></string-name>, <string-name><given-names>A. Y. S.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>E. J.</given-names>
<surname>Williamson</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Forbes</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Wing</surname></string-name>, <string-name><given-names>H. I.</given-names>
<surname>McDonald</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Bates</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bacon</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Walker</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Evans</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Inglesby</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mehrkar</surname></string-name>, <string-name><given-names>H. J.</given-names>
<surname>Curtis</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>DeVito</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Croker</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Drysdale</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Cockburn</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Parry</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Hester</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Harper</surname></string-name>, <string-name><given-names>I. J.</given-names>
<surname>Douglas</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Tomlinson</surname></string-name>, <string-name><given-names>S. J. W.</given-names>
<surname>Evans</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Grieve</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Harrison</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Rowan</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Khunti</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Chaturvedi</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Smeeth</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Goldacre</surname></string-name>, <collab>OpenSAFELY Collaborative</collab></person-group>, 
<article-title>Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform</article-title>. <source>Lancet</source>
<volume>397</volume>, 
<fpage>1711</fpage>&#x02013;<lpage>1724</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33939953</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Padellini</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Jersakova</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Diggle</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Holmes</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>King</surname></string-name>, <string-name><given-names>B. C. L.</given-names>
<surname>Lehmann</surname></string-name>, <string-name><given-names>A.-M.</given-names>
<surname>Mallon</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Nicholson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Richardson</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Blangiardo</surname></string-name></person-group>, 
<article-title>Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: A population-based ecological study</article-title>. <source>Lancet Reg. Health Eur.</source>
<volume>15</volume>, 
<fpage>100322</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35187517</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Razieh</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Shabnam</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Dambha-Miller</surname></string-name>, <string-name><given-names>E. J. A.</given-names>
<surname>Morris</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Yates</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chudasama</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zaccardi</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gillies</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Banerjee</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pareek</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Lacey</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Khunti</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Islam</surname></string-name></person-group>, 
<article-title>Socioeconomic inequalities in risk of infection with SARS-CoV-2 delta and omicron variants in the UK, 2020-22: analysis of the longitudinal COVID-19 Infection Survey</article-title>. <source>BMJ Med.</source>
<volume>3</volume>, 
<fpage>e000624</fpage> (<year>2024</year>).</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. J.</given-names>
<surname>Wood</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Sanchez</surname></string-name>, <string-name><given-names>P. R.</given-names>
<surname>Bessell</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Wightman</surname></string-name>, <string-name><given-names>R. R.</given-names>
<surname>Kao</surname></string-name></person-group>, 
<article-title>Assessing the importance of demographic risk factors across two waves of SARS-CoV-2 using fine-scale case data</article-title>. <source>PLOS Comput. Biol.</source>
<volume>19</volume>, 
<fpage>e1011611</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">38011282</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="webpage">UK Ministry of Housing, Communities and Local Government, &#x0201c;The English Indices of Deprivation 2019&#x0201d; (2019). <ext-link xlink:href="https://assets.publishing.service.gov.uk/media/5d8e26f6ed915d5570c6cc55/IoD2019_Statistical_Release.pdf" ext-link-type="uri">https://assets.publishing.service.gov.uk/media/5d8e26f6ed915d5570c6cc55/IoD2019_Statistical_Release.pdf</ext-link>.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Morrissey</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Spooner</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Salter</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Shaddick</surname></string-name></person-group>, 
<article-title>Area level deprivation and monthly COVID-19 cases: The impact of government policy in England</article-title>. <source>Soc. Sci. Med.</source>
<volume>289</volume>, 
<fpage>114413</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34563867</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="webpage">T. Phillips, Oxford Covid-19 Government Response Tracker (OxCGRT), Blavatnik School of Government, University of Oxford, GitHub (2023); <ext-link xlink:href="https://github.com/OxCGRT/covid-policy-tracker" ext-link-type="uri">https://github.com/OxCGRT/covid-policy-tracker</ext-link>.</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Vandentorren</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sma&#x000ef;li</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Chatignoux</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Maurel</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Alleaume</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Neufcourt</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kelly-Irving</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Delpierre</surname></string-name></person-group>, 
<article-title>The effect of social deprivation on the dynamic of SARS-CoV-2 infection in France: A population-based analysis</article-title>. <source>Lancet Public Health</source>
<volume>7</volume>, 
<fpage>e240</fpage>&#x02013;<lpage>e249</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35176246</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Rohleder</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Costa</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Bozorgmehr</surname></string-name></person-group>, 
<article-title>Area-level socioeconomic deprivation, non-national residency, and Covid-19 incidence: A longitudinal spatiotemporal analysis in Germany</article-title>. <source>EClinicalMedicine</source>
<volume>49</volume>, 
<fpage>101485</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35719293</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Magesh</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>John</surname></string-name>, <string-name><given-names>W. T.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mattingly-app</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jain</surname></string-name>, <string-name><given-names>E. Y.</given-names>
<surname>Chang</surname></string-name>, <string-name><given-names>W. M.</given-names>
<surname>Ongkeko</surname></string-name></person-group>, 
<article-title>Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: A systematic review and meta-analysis</article-title>. <source>JAMA Netw. Open</source>
<volume>4</volume>, 
<fpage>e2134147</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34762110</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="webpage">Department of Health and Social Care, &#x0201c;Coronavirus (COVID-19): Scaling up testing programmes&#x0201d; (2020); <ext-link xlink:href="https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf" ext-link-type="uri">https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf</ext-link>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="webpage">UK Health Security Agency, &#x0201c;Testing Times: striving for quality in the COVID-19 national testing service, April 2020 to March 2022&#x0201d; (2020); <ext-link xlink:href="https://www.gov.uk/government/publications/coronavirus-covid-19-scaling-up-testing-programmes" ext-link-type="uri">www.gov.uk/government/publications/coronavirus-covid-19-scaling-up-testing-programmes</ext-link>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="webpage">NHS England, &#x0201c;National vaccination programmes&#x0201d; (2021); <ext-link xlink:href="https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/" ext-link-type="uri">www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/</ext-link>.</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Lopez Bernal</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gower</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Gallagher</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Simmons</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Thelwall</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Stowe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Tessier</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Groves</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Dabrera</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Myers</surname></string-name>, <string-name><given-names>C. N. J.</given-names>
<surname>Campbell</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Amirthalingam</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Edmunds</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Zambon</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Brown</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hopkins</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chand</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ramsay</surname></string-name></person-group>, 
<article-title>Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant</article-title>. <source>N. Engl. J. Med.</source>
<volume>385</volume>, 
<fpage>585</fpage>&#x02013;<lpage>594</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34289274</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Lopez Bernal</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gower</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Robertson</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Stowe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Tessier</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Simmons</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cottrell</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Roberts</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>O&#x02019;Doherty</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Brown</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Cameron</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Stockton</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>McMenamin</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ramsay</surname></string-name></person-group>, 
<article-title>Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study</article-title>. <source>BMJ</source>
<volume>373</volume>, 
<fpage>n1088</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33985964</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Chua</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Feng</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Lewnard</surname></string-name>, <string-name><given-names>S. G.</given-names>
<surname>Sullivan</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>Blyth</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lipsitch</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Cowling</surname></string-name></person-group>, 
<article-title>The use of test-negative controls to monitor vaccine effectiveness: A systematic review of methodology</article-title>. <source>Epidemiology</source>
<volume>31</volume>, 
<fpage>43</fpage>&#x02013;<lpage>64</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31609860</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="webpage">WHO, &#x0201c;Evaluation of COVID-19 vaccine effectiveness: Interim guidance, 17 March 2021&#x0201d; (2021); <ext-link xlink:href="https://iris.who.int/handle/10665/340301" ext-link-type="uri">https://iris.who.int/handle/10665/340301</ext-link>.</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. M.</given-names>
<surname>Bar-On</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Goldberg</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Mandel</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Bodenheimer</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Freedman</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kalkstein</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Mizrahi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Alroy-Preis</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Ash</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Milo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Huppert</surname></string-name></person-group>, 
<article-title>Protection of BNT162b2 vaccine booster against Covid-19 in Israel</article-title>. <source>N. Engl. J. Med.</source>
<volume>385</volume>, 
<fpage>1393</fpage>&#x02013;<lpage>1400</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34525275</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Chemaitelly</surname></string-name>, <string-name><given-names>H. M.</given-names>
<surname>Yassine</surname></string-name>, <string-name><given-names>F. M.</given-names>
<surname>Benslimane</surname></string-name>, <string-name><given-names>H. A.</given-names>
<surname>Al Khatib</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Tang</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Hasan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Malek</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Coyle</surname></string-name>, <string-name><given-names>H. H.</given-names>
<surname>Ayoub</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Al Kanaani</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Al Kuwari</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Jeremijenko</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Kaleeckal</surname></string-name>, <string-name><given-names>A. N.</given-names>
<surname>Latif</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Shaik</surname></string-name>, <string-name><given-names>H. F.</given-names>
<surname>Abdul Rahim</surname></string-name>, <string-name><given-names>G. K.</given-names>
<surname>Nasrallah</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Al Kuwari</surname></string-name>, <string-name><given-names>H. E.</given-names>
<surname>Al Romaihi</surname></string-name>, <string-name><given-names>M. H.</given-names>
<surname>Al-Thani</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Al Khal</surname></string-name>, <string-name><given-names>A. A.</given-names>
<surname>Butt</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Bertollini</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>Abu-Raddad</surname></string-name></person-group>, 
<article-title>mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar</article-title>. <source>Nat. Med.</source>
<volume>27</volume>, 
<fpage>1614</fpage>&#x02013;<lpage>1621</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34244681</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Vasileiou</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Simpson</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kerr</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Agrawal</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Akbari</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bedston</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Beggs</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Bradley</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chuter</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>De Lusignan</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Docherty</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Ford</surname></string-name>, <string-name><given-names>F. R.</given-names>
<surname>Hobbs</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Joy</surname></string-name>, <string-name><given-names>S. V.</given-names>
<surname>Katikireddi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Marple</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>McCowan</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>McGagh</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>McMenamin</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Moore</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Murray</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Ritchie</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Shah</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Stock</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Torabi</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Tsang</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Wood</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Woolhouse</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Robertson</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sheikh</surname></string-name></person-group>, 
<article-title>Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study</article-title>. <source>Lancet</source>
<volume>397</volume>, 
<fpage>1646</fpage>&#x02013;<lpage>1657</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33901420</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Nafilyan</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Bermingham</surname></string-name>, <string-name><given-names>I. L.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Morgan</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zaccardi</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Khunti</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Stanborough</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Banerjee</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Doidge</surname></string-name></person-group>, 
<article-title>Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England</article-title>. <source>Nat. Commun.</source>
<volume>14</volume>, 
<fpage>1541</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">36973247</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Endo</surname></string-name>, <collab>Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group</collab>, <string-name><given-names>S.</given-names>
<surname>Abbott</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Kucharski</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Funk</surname></string-name></person-group>, 
<article-title>Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China</article-title>. <source>Wellcome Open Res.</source>
<volume>5</volume>, 
<fpage>67</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32685698</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="other">E. B. Hodcroft, M. S. Wohlfender, R. A. Neher, J. Riou, C. L. Althaus, Estimating <italic toggle="yes">R<sub>e</sub></italic> and overdispersion in secondary cases from the size of identical sequence clusters of SARS-CoV-2. medRxiv 24307940 [Preprint] (2024). <pub-id pub-id-type="doi">10.1101/2024.05.26.24307940</pub-id>.</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>COVID-19 Forecasting Team</collab></person-group>, 
<article-title>Variation in the COVID-19 infection&#x02013;fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysis</article-title>. <source>Lancet</source>
<volume>399</volume>, 
<fpage>1469</fpage>&#x02013;<lpage>1488</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35219376</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. W.</given-names>
<surname>Papageorge</surname></string-name>, <string-name><given-names>M. V.</given-names>
<surname>Zahn</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Belot</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Van Den Broek-Altenburg</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Jamison</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Tripodi</surname></string-name></person-group>, 
<article-title>Socio-demographic factors associated with self-protecting behavior during the Covid-19 pandemic</article-title>. <source>J. Popul. Econ.</source>
<volume>34</volume>, 
<fpage>691</fpage>&#x02013;<lpage>738</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33462529</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="webpage">Imperial College London/YouGov, &#x0201c;COVID-19 behaviour tracker&#x0201d; (2020); <ext-link xlink:href="https://www.imperial.ac.uk/global-health-innovation/what-we-do/our-response-to-covid-19/covid-19-behaviour-tracker/" ext-link-type="uri">www.imperial.ac.uk/global-health-innovation/what-we-do/our-response-to-covid-19/covid-19-behaviour-tracker/</ext-link>.</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="other">T. Rawson, W. Hinsley, R. Sonabend, E. Semenova, A. Cori, N. M. Ferguson, The impact of health inequity on regional variation of COVID-19 transmission in England. medRxiv 24306121 [Preprint] (2024). <pub-id pub-id-type="doi">10.1101/2024.04.20.24306121</pub-id>.</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. D.</given-names>
<surname>Nagar</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>N&#x000e1;poles</surname></string-name>, <string-name><given-names>I. K.</given-names>
<surname>Jordan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Mari&#x000f1;o-Ram&#x000ed;rez</surname></string-name></person-group>, 
<article-title>Socioeconomic deprivation and genetic ancestry interact to modify type 2 diabetes ethnic disparities in the United Kingdom</article-title>. <source>EClinicalMedicine</source>
<volume>37</volume>, 
<fpage>100960</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34386746</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Ramachandran</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Snehalatha</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Shetty</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nanditha</surname></string-name></person-group>, 
<article-title>Trends in prevalence of diabetes in Asian countries</article-title>. <source>World J. Diabetes</source>
<volume>3</volume>, 
<fpage>110</fpage>&#x02013;<lpage>117</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22737281</pub-id>
</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Stowe</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Kirsebom</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ramsay</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Bernal</surname></string-name></person-group>, 
<article-title>Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>5736</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36180428</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Bajaj</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Creswell</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Naidoo</surname></string-name>, <string-name><given-names>J. L.-H.</given-names>
<surname>Tsui</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Kolade</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Nicholson</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Lehmann</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Hay</surname></string-name>, <string-name><given-names>M. U. G.</given-names>
<surname>Kraemer</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Aguas</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Donnelly</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Fowler</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hopkins</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Cantrell</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Dahal</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Stepniewska</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Voysey</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Lambert</surname></string-name>, <collab>EY-Oxford Health Analytics Consortium</collab></person-group>, 
<article-title>COVID-19 testing and reporting behaviours in England across different sociodemographic groups: a population-based study using testing data and data from community prevalence surveillance surveys</article-title>. <source>Lancet Digit. Health</source>
<volume>6</volume>, 
<fpage>e778</fpage>&#x02013;<lpage>e790</lpage> (<year>2024</year>).<pub-id pub-id-type="pmid">39455191</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Platt</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Warwick</surname></string-name></person-group>, 
<article-title>COVID-19 and ethnic inequalities in England and Wales</article-title>. <source>Fisc. Stud.</source>
<volume>41</volume>, 
<fpage>259</fpage>&#x02013;<lpage>289</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32836536</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. N.</given-names>
<surname>Perez-Guzman</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Knock</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Imai</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Rawson</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Nazzareno Santoni</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Alcada</surname></string-name>, <string-name><given-names>L. K.</given-names>
<surname>Whittles</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Thekke Kanapram</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Sonabend</surname></string-name>, <string-name><given-names>K. A. M.</given-names>
<surname>Gaythorpe</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Hinsley</surname></string-name>, <string-name><given-names>R. G.</given-names>
<surname>FitzJohn</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Volz</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Verity</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Ferguson</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cori</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Baguelin</surname></string-name></person-group>, 
<article-title>Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England</article-title>. <source>Nat. Commun.</source>
<volume>14</volume>, 
<fpage>4279</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37460537</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="webpage">&#x0201c;Independent report Chapter 6: Testing&#x0201d; (2023); <ext-link xlink:href="https://www.gov.uk/government/publications/technical-report-on-the-covid-19-pandemic-in-the-uk/chapter-6-testing#introduction" ext-link-type="uri">www.gov.uk/government/publications/technical-report-on-the-covid-19-pandemic-in-the-uk/chapter-6-testing#introduction</ext-link>.</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="webpage">&#x0201c;Stay at home: Guidance for households with possible or confirmed coronavirus (COVID-19) infection&#x0201d; (2022); <ext-link xlink:href="https://www.gov.uk/government/publications/covid-19-stay-at-home-guidance/stay-at-home-guidance-for-households-with-possible-coronavirus-covid-19-infection#financial-or-other-practical-support" ext-link-type="uri">www.gov.uk/government/publications/covid-19-stay-at-home-guidance/stay-at-home-guidance-for-households-with-possible-coronavirus-covid-19-infection#financial-or-other-practical-support</ext-link>.</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="webpage">ONS, Census. <ext-link xlink:href="https://www.ons.gov.uk/census" ext-link-type="uri">www.ons.gov.uk/census</ext-link>.</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="webpage">Office of National Statistics, Office of National Statistics Census 2021, Create a custom dataset. <ext-link xlink:href="https://www.ons.gov.uk/datasets/create" ext-link-type="uri">www.ons.gov.uk/datasets/create</ext-link>.</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="webpage">ONS, Full list of local COVID alert levels by area. <ext-link xlink:href="https://www.gov.uk/guidance/full-list-of-local-covid-alert-levels-by-area" ext-link-type="uri">www.gov.uk/guidance/full-list-of-local-covid-alert-levels-by-area</ext-link>.</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names>
<surname>Laird</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Olivier</surname></string-name></person-group>, 
<article-title>Covariance analysis of censored survival data using log-linear analysis techniques</article-title>. <source>J. Am. Stat. Assoc.</source>
<volume>76</volume>, 
<fpage>231</fpage>&#x02013;<lpage>240</lpage> (<year>1981</year>).</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Stoica</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Selen</surname></string-name></person-group>, 
<article-title>Model-order selection</article-title>. <source>IEEE Signal Process. Mag.</source>
<volume>21</volume>, 
<fpage>36</fpage>&#x02013;<lpage>47</lpage> (<year>2004</year>).</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. O.</given-names>
<surname>Kv&#x000e5;lseth</surname></string-name></person-group>, 
<article-title>Cautionary Note about <italic toggle="yes">R</italic><sup>2</sup></article-title>. <source>Am. Stat.</source>
<volume>39</volume>, 
<fpage>279</fpage>&#x02013;<lpage>285</lpage> (<year>1985</year>).</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="webpage">H2O, H2O.ai. h2o: R Interface for H2O. R package version 3.42.0.2, GitHub (2023). <ext-link xlink:href="https://github.com/h2oai/h2o-3" ext-link-type="uri">https://github.com/h2oai/h2o-3</ext-link>.</mixed-citation></ref></ref-list></back></article>